Objective: The efficacy of intravesical chemotherapy in abolishing small papillary recurrences of non-muscle-invasive bladder cancer (NMIBC), the disease-free interval in responders and patients' preferences were explored. Methods: When a small (≤1 cm) papillary recurrence of a NMIBC was diagnosed, the patient could choose between immediate transurethral resection of the bladder (TURB) or four weekly intravesical instillations with mitomycin C (MMC) or epirubicin (ERC). Control cystoscopy was scheduled 2-3 weeks after the last instillation. Complete remission was defined as total disappearance of all papillary tumours and negative cytology. Results: 25 patients with 47 recurrence episodes were recruited from February 2003 until August 2011. The median follow-up was 35 months. After exclusion of 2 patients with intolerance to the instillations, 45 study episodes could be analysed. All patients to whom this was proposed preferred the instillations over immediate TURB. Complete, partial and no response was seen in 23 (51%), 6 (13%) and 16 (36%) out of 45 episodes, respectively. The median disease-free interval after complete remission was 16 months (95% confidence interval 9-24). Conclusions: Small papillary recurrences of NMIBC completely disappear in about half of the cases receiving four weekly bladder instillations with MMC or ERC. This is followed by a disease-free interval. Intravesical chemotherapy was preferred by all patients over immediate TURB.

Keywords:
Mitomycin C, Epirubicin, Intravesical chemotherapy, Urothelial bladder neoplasm, Chemoresection
1.
Mishina T, Oda K, Murata S, Ooe H, Mori Y: Mitomycin C bladder instillation therapy for bladder tumors. J Urol 1975;114:217-219.
2.
Bracken RB, Swanson DA, Johnson DE, De Furia D, von Eschenbach AC, Crooke S: Role of intravesical mitomycin C in management of superficial bladder tumors. Urology 1980;16:11-15.
3.
Harrison GS, Green DF, Newling DW, Richards B, Robinson MR, Smith PH: A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer. Br J Urol 1983;55:676-679.
4.
Hetherington JW, Newling DW, Robinson MR, Smith PH, Adib RS, Whelan P: Intravesical mitomycin C for the treatment of recurrent superficial bladder tumours. Br J Urol 1987;59:239-241.
5.
Soloway MS: Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients. J Urol 1985;134:1107-1109.
6.
Bono AV, Hall RR, Denis L, Lovisolo JA, Sylvester R: Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group. Eur Urol 1996;29:385-390.
7.
Brausi M, Campo B, Pizzocaro G, Rigatti P, Parma A, Mazza G, Vicini A, Stephen RL: Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative phase II study. Urology 1998;51:506-509.
8.
Maffezzini M, Simonato A, Zanon M, Raber M, Carmignani G: Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer. J Urol 1996;155:91-93.
9.
Colombo R, Brausi M, Da Pozzo L, Salonia A, Montorsi F, Scattoni V, Roscigno M, Rigatti P: Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. A pilot study on marker lesion. Eur Urol 2001;39:95-100.
10.
Hamdy FC, Hastie KJ, Kerry R, Williams JL: Mitomycin-C in superficial bladder cancer. Is long-term maintenance therapy worthwhile after initial treatment? Br J Urol 1993;71:183-186.
11.
Calais da Silva F, Denis L, Bono A, Bollack C, Bouffioux C: Intravesical chemoresection with 4'-epi-doxorubicin in patients with superficial bladder tumors. Eur Urol 1988;14:207-209.
12.
Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, Newling D, Bouffioux C, Sylvester RJ; EORTC Genito-Urinary Tract Cancer Collaborative Group: Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002;41:523-531.
13.
Colombo R, Rocchini L, Suardi N, Benigni F, Colciago G, Bettiga A, Pellucchi F, Maccagnano C, Briganti A, Salonia A, Rigatti P, Montorsi F: Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol 2012;62:797-802.
14.
Serretta V, Pavone C, Ingargiola GB, Daricello G, Allegro R, Pavone-Macaluso M: TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years. Eur Urol 2004;45:730-735; discussion 735-736.
15.
Sylvester RJ, Oosterlinck W, Witjes JA: The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 2008;53:709-719.
16.
Masters JR, Popert RJ, Thompson PM, Gibson D, Coptcoat MJ, Parmar MK: Intravesical chemotherapy with epirubicin: a dose response study. J Urol 1999;161:1490-1493.
17.
Hinotsu S, Akaza H, Ohashi Y, Kotake T: Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 1999;86:1818-1826.
18.
Oosterlinck W, Bono AV, Mack D, Hall R, Sylvester R, de Balincourt C, Brausi M; members of the EORTC GU Group: Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions. Eur Urol 2001;40:515-517.
19.
Suer E, Ozcan C, Baltaci S, Gulpinar O, Burgu B, Haliloglu A, Beduk Y: Time between first and second transurethral resection of bladder tumors in patients with high-grade T1 tumors: is it a risk factor for residual tumor detection? Urol Int 2013;91:182-186.
20.
Gontero P, Gillo A, Fiorito C, Oderda M, Pacchioni D, Casetta G, Peraldo F, Zitella A, Tizzani A, Ricceri F: Prognostic factors of ‘high-grade' Ta bladder cancers according to the WHO 2004 classification: are these equivalent to ‘high-risk' non-muscle-invasive bladder cancer? Urol Int 2014;92:136-142.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.